Effects of topical nasal decongestants, L-arginine and nitric oxide synthase inhibition, on nasal cavity nitric oxide levels and nasal cavity volume in man

American Journal of Rhinology

Volumn 10, Issue 6, 1996, Pages 399-408

  Rinder, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CAPSAICIN; DECONGESTIVE AGENT; HISTAMINE; N(G) NITROARGININE METHYL ESTER; NAPHAZOLINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYMETAZOLINE; PHENYLEPHRINE;

ADULT; ARTICLE; CHEMOLUMINESCENCE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; NOSE CAVITY; TOPICAL DRUG ADMINISTRATION;

EID: 0030477950     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142, 1991.
2. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB 6:3051-3056, 1992.
3. Croen KD. Evidence for an antiviral effect of nitric oxide. J Clin Invest 91:2446-2452, 1993.
4. Gustafsson LE, Leone AM, Persson MG, et al. Endogenous nitric oxide is present in exhaled air of rabbits, guinea-pigs, and humans. Biochem Biophys Res Commun 181:852-857, 1991.
5. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 6:1368-1370, 1993.
6. Lundberg JON, Weitzberg E, Nordvall SL, Kuylenstierna R, Lundberg JM, Alving K. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Eur Respir J 7:1501-1504, 1994.
7. Gerlach H, Rossaint R, Pappert D. Autoinhalation of nitric oxide after endogenous synthesis in nasopharynx. Lancet 343:518-519, 1994.
8. Lundberg JON, Rinder J, Weitzberg E, Lundberg JM, Alving K. Nasally exhaled nitric oxide in humans originates mainly in the paranasal sinuses. Acta Physiol Scand 152:431-432, 1994.